Expression and activity profiles of DPP IV/CD26 and NEP/CD10 glycoproteins in the human renal cancer are tumor-type dependent

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Varona, Adolfo ^a   Blanco, Lorena ^a   Perez, Itxaro ^a   Gil, Javier ^a   Irazusta, Jon ^a   López, José I ^b   Candenas, M Luz ^c   Pinto, Francisco M ^c   Larrinaga, Gorka ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b HOSPITAL DE CRUCES   (Spain)

^c INSTITUTO DE INVESTIGACIONES QUÍMICAS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; MEMBRANE METALLOENDOPEPTIDASE; MEMBRANE PROTEIN; MESSENGER RNA; DPP4 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CANCER; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; NEPHRON; ONCOCYTOMA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; CANCER STAGING; COMPARATIVE STUDY; ENZYMOLOGY; GENETICS; KIDNEY TUMOR; MIDDLE AGED; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADENOMA, OXYPHILIC; AGED; ANTIGENS, CD26; CARCINOMA, RENAL CELL; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEPRILYSIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 77951973029     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-193     Document Type: Article

References (44)

1. Bannasch P, Zerban H. Animal models and renal carcinogenesis. Tumors and tumorlike conditions of the kidneys and ureters 1990, 1-34. New York: Churchill-Livingstone, Eble JN.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer Statistics, 2007. CA Cancer J Clin 2007, 57:43-66. 10.3322/canjclin.57.1.43, 17237035.
3. López-Beltrán A, Scarpelli M, Montironi R, Kirkali Z. 2004 WHO classification of the renal tumors of the adults. Eur Urol 2006, 49:798-805. 10.1016/j.eururo.2005.11.035, 16442207.
4. Jin JS, Hsieh DS, Lin YF, Wang JY, Sheu LF, Lee WH. Increasing expression of extracellular matrix metalloprotease inducer in renal cell carcinoma: tissue microarray analysis of immunostaining score with clinicopathological parameters. Int J Urol 2006, 13:573-580. 10.1111/j.1442-2042.2006.01353.x, 16771728.
5. Patraki E, Cardillo MR. Quantitative immunohistochemical analysis of matrilysin 1 (MMP-7) in various renal cell carcinoma subtypes. Int J Immunopathol Pharmacol 2007, 20:697-705.
6. Pro B, Dang NH. CD26/dipeptidyl peptidase IV and its role in cancer. Histol Histopathol 2004, 19:1345-1351.
7. Sumitomo M, Shen R, Nanus D. Involvement of neutral endopeptidase in neoplastic progression. Biochim Biophys Acta 2005, 1751:52-59.
8. Raguin O, Fournié-Zaluski MC, Romieu A, Pèlegrin A, Chatelet F, Pélaprat D, Barbet J, Roques BP, Gruaz-Guyon A. A labeled Neutral Endopeptidase Inhibitor as a potential tool for tumor diagnosis and prognosis. Angew Chem Int Ed 2005, 44:4058-4061.
9. Busek P, Malík R, Sedo A. Dipeptidyl peptidase IV activity and/or structure homologues (DASH) and their substrates in cancer. Int J Biochem Cell Biol 2004, 36:408-421. 10.1016/S1357-2725(03)00262-0, 14687920.
10. Santos RAS, Ferreira AJ, Simoes e Silva AC. Recent advances in the angiotensin-converting enzyme 2-angiotensin (1-7)-Mas axis. Exp Physiol 2008, 93:519-527. 10.1113/expphysiol.2008.042002, 18310257.
11. Kelly T. Fibroblast interaction protein-α and dipeptidyl peptidase IV (CD26): Cell-surface proteases that activate cell signalling and are potential targets for cancer therapy. Drug Resist Updat 2005, 8:51-58. 10.1016/j.drup.2005.03.002, 15939342.
12. Varona A, Blanco L, López JI, Gil J, Agirregoitia E, Irazusta J, Larrinaga G. Altered levels of acid, basic, and neutral peptidase activity and expression in human clear cell renal cell carcinoma. Am J Physiol-Renal Physiol 2007, 292:F780-F788. 10.1152/ajprenal.00148.2006, 16985214.
13. Blanco L, Larrinaga G, Pérez I, López JI, Gil J, Agirregoitia E, Varona A. Acid, basic and neutral peptidases present different profiles in chromophobe renal cell carcinoma and in oncocytoma. Am J Physiol-Renal Physiol 2008, 294:F850-F858. 10.1152/ajprenal.00469.2007, 18216146.
14. Sobin LH, Wittekind C. TNM Classification of Malignant Tumors. 2002, New York: Wiley-Liss, 6.
15. Furhman SA, Lasky LC, Limas. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982, 6:655-663.
16. Duke-Cohan JS, Morimoto C, Rocker JA, Schlossman SF. A novel form of dipeptidylpeptidase IV found in human serum. Isolation, characterization, and comparison with T lymphocyte membrane dipeptidylpeptidase IV (CD26). J Biol Chem 1995, 270:14107-14. 10.1074/jbc.270.23.14107, 7539799.
17. Liu WJ, Hansen PJ. Progesterone-induced secretion of dypeptidyl peptidase-IV (cluster differentiation antigen-26) by the uterine endometrium of the ewe and cow that costimulates lymphocyte proliferation. Endocrinology 1995, 136:779-87. 10.1210/en.136.2.779, 7835310.
18. Florentin D, Sassi A, Roques BP. A highly sensitive fluorimetric assay for "enkephalinase", a neutral metalloendopeptidase that releases Tyr-Gly-Gly from enkephalins. Anal Biochem 1984, 141:62-69. 10.1016/0003-2697(84)90425-1, 6388410.
19. Patak E, Candenas ML, Pennefather JN, Ziccone S, Lilley A, Martín JD, Flores C, Mantecón AG, Pinto FM. Tachykinins and tachykinin receptors in human uterus. Br J Pharmacol 2003, 139:523-532. 10.1038/sj.bjp.0705279, 1573878, 12788812.
20. Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 2003, 132:365-368.
21. Jung M, Ramankulov A, Roigas J, Johannsen M, Ringsdorf M, Kristiansen G, Jung K. In search of suitable reference genes for gene expression studies of human renal cell carcinoma by real-time PCR. BMC Mol Biol 2007, 8:47-60. 10.1186/1471-2199-8-47, 1913536, 17559644.
22. Radonic A, Thulke S, Mackay IM, Landt O, Siegert W, Nitsche A. Guideline to reference gene selection for quantitative real-time PCR. Biochem Biophys Res Commun 2004, 313:856-862. 10.1016/j.bbrc.2003.11.177, 14706621.
23. Pinto FM, Almeida TA, Hernandez M, Devillier P, Advenier C, Candenas ML. mRNA expression of tachykinins and tachykinin receptors in different human tissues. Eur J Pharmacol 2004, 494:233-239. 10.1016/j.ejphar.2004.05.016, 15212980.
24. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002, 18:1-11.
25. Carl-McGrath S, Lendeckel U, Ebert M, Röcken C. Ectopeptidases in tumour biology: A review. Histol Histopathol 2006, 21:1339-1353.
26. Havre PA, Abe M, Urasaki Y, Ohnuma K, Morimoto C, Dang NH. The role of CD26/dipeptidyl peptidase IV in cancer. Front Biosci 2008, 13:1634-1645. 10.2741/2787, 17981655.
27. Bauvois B. Transmembrane proteases in cell growth and invasion: new contributors to angiogenesis?. Oncogene 2004, 23:317-329. 10.1038/sj.onc.1207124, 14724562.
28. Larrinaga G, Lopez JI, Casis L, Blanco L, Gil J, Agirregoitia E, Varona A. Cystinyl aminopeptidase activity is decreased in renal cell carcinomas. Regul Pept 2007, 144:56-61. 10.1016/j.regpep.2007.06.002, 17692401.
29. Avery AK, Beckstead J, Renshaw JJ, Corless CL. Use of antibodies to RCC and CD10 in the differential diagnosis of Renal Neoplasms. Am J Surg Pathol 2000, 24:203-210. 10.1097/00000478-200002000-00006, 10680888.
30. Langner C, Ratschek M, Rehak P, Schips L, Zigeuner R. CD10 is a diagnostic and prognostic marker in renal malignancies. Histopathology 2004, 45:460-467. 10.1111/j.1365-2559.2004.01982.x, 15500649.
31. Zhou M, Roma A, Magi-Galluzzi C. The usefulness of immunohistochemical markers in the differential diagnosis of renal neoplasms. Clin Lab Med 2005, 25:247-257. 10.1016/j.cll.2005.01.004, 15848735.
32. Martignoni G, Pea M, Brunelli M, Chilosi M, Zamó A, Bertaso M, Cossu-Rocca P, Eble JN, Mikuz G, Puppa G, Badoual C, Ficarra V, Novella G, Bonetti F. CD10 is expressed in a subset of chromophobe renal cell carcinomas. Mod Pathol 2004, 17:1455-1463. 10.1038/modpathol.3800236, 15286660.
33. Droz D, Zachar D, Charbit L, Gogusev J, Chrétein Y, Iris L. Expression of the human nephron differentiation molecules in renal cell carcinomas. Am J Pathol 1990, 137:895-905. 1877557, 1699423.
34. Inamoto T, Yamochi T, Ohnuma K, Iwata S, Kina S, Inamoto S, Tchibana M, Katsuoka Y, Dang NH, Morimoto C. Anti-CD26 monoclonal antibody-mediated G1-S arrest on human renal clear cell carcinoma Caki-2 is associated with retinoblastoma substrate dephosphorylation, cyclin-dependent kinase 2 reduction, p27(kip1) enhancement, and disruption of binding to the extracellular matrix. Clin Cancer Res 2006, 12:3470-3477. 10.1158/1078-0432.CCR-06-0361, 16740772.
35. Wesley U, Albino AP, Tiwari S, Houghton AN. A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells. J Exp Med 1999, 190:311-322. 10.1084/jem.190.3.311, 2195594, 10430620.
36. Kikkawa F, Kajiyama H, Shibata K, Ino K, Nomura S, Mizutani S. Dipeptidyl peptidase IV in tumor progression. Biochim Biophys Acta 2005, 1751:45-51.
37. Duke-Cohan JS, Morimoto C, Rocker JA, Schlossman SF. A novel form of dipeptidylpeptidase IV found in human serum. Isolation, characterization, and comparison with T lymphocyte membrane dipeptidylpeptidase IV (CD26). J Biol Chem 1995, 270:14107-14. 10.1074/jbc.270.23.14107, 7539799.
38. Olivo Rdo A, Teixeira Cde F, Silveira PF. Representative aminopeptidases and prolyl endopeptidase from murine macrophages: comparative activity levels in resident and elicited cells. Biochem Pharmacol 2005, 69:1441-1450. 10.1016/j.bcp.2005.03.002, 15857608.
39. Cordero OJ, Ayude D, Nogueira M, Rodríguez-Berrocal FJ, de La Cadena MP. Preoperative serum CD26 levels: diagnostic efficiency and predictive value for colorectal cancer. Br J Cancer 2000, 83:1139-1146. 10.1054/bjoc.2000.1410, 2363587, 11027426.
40. Petraki CD, Gregorakis AK, Vaslamatzis MM, Papanastasiou PA, Yousef GM, Levesque MA, Diamandis EP. Prognostic implications of the immunohistochemical expression of human kallikreins 5, 6, 10 and 11 in renal cell carcinoma. Tumour Biol 2006, 27:1-7. 10.1159/000090150, 16340244.
41. Papandreou CN, Usmani B, Geng Y, Bogenrieder T, Freeman R, Wilk S, Finstad CL, Reuter VE, Powell CT, Scheinberg D, Magill C, Scher HI, Albino AP, Nanus DM. Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nat Med 1998, 4:50-57. 10.1038/nm0198-050, 9427606.
42. Göhring B, Holzhausen HJ, Meye A, Heynemann H, Rebmann U, Langner J, Riemann D. Endopeptidase 24.11/CD10 is down-regulated in renal cell cancer. Int J Mol Med 1998, 2:409-414.
43. Goodman OB, Febbraio M, Simantov R, Zheng R, Shen R, Silverstein RL, Nanus DM. Neprilysin inhibits angiogenesis via proteolysis of fibroblast growth factor-2. J Biol Chem 2006, 281:33597-33605. 10.1074/jbc.M602490200, 16940054.
44. Bonifant CL, Kim JS, Waldman T. NHERFs, NEP, MAGUKs, and more: interactions that regulate PTEN. J Cell Biochem 2007, 102:878-885. 10.1002/jcb.21518, 17786934.